NCT03909295 - An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 7, 2019

Primary Completion Date

November 19, 2019

Study Completion Date

November 19, 2019

Conditions

Heart Failure With Preserved Ejection Fraction (HFpEF)

Interventions

DRUG

LCZ696

Starting dose was either 50 mg b.i.d. or 100 mg b.i.d. largely depending on the last dose level taken by the patient at the time of completing PARAGON-HF and patient condition. The dose level was gradually up-titrated with the goal of reaching the target dose of 200 mg b.i.d. as soon as tolerated by the patient

Trial Locations (17)

489-8642

Novartis Investigative Site, Seto

818-8516

Novartis Investigative Site, Chikushino-shi

503-8502

Novartis Investigative Site, Ōgaki

371 8511

Novartis Investigative Site, Maebashi

920 8650

Novartis Investigative Site, Kanazawa

020 0066

Novartis Investigative Site, Morioka

769-1695

Novartis Investigative Site, Kan’onjichō

760 8557

Novartis Investigative Site, Takamatsu

227-8501

Novartis Investigative Site, Yokohama

236 0051

Novartis Investigative Site, Yokohama

980 8574

Novartis Investigative Site, Sendai

634 8522

Novartis Investigative Site, Kashihara

350-1305

Novartis Investigative Site, Sayama

525 8585

Novartis Investigative Site, Kusatsu

192-0918

Novartis Investigative Site, Hachiōji

173-8610

Novartis Investigative Site, Itabashi-ku

142-8666

Novartis Investigative Site, Shinagawa-ku